On Tuesday, CRISPR Therapeutics AG (NASDAQ: CRSP) opened higher 2.95% from the last session, before settling in for the closing price of $36.95. Price fluctuations for CRSP have ranged from $30.04 to $67.88 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -33.62%. Company’s average yearly earnings per share was noted -25.38% at the time writing. With a float of $82.80 million, this company’s outstanding shares have now reached $86.36 million.
Let’s determine the extent of company efficiency that accounts for 393 employees. In terms of profitability, gross margin is -259.34%, operating margin of -1313.44%, and the pretax margin is -1056.74%.
CRISPR Therapeutics AG (CRSP) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of CRISPR Therapeutics AG is 4.13%, while institutional ownership is 69.15%. The most recent insider transaction that took place on May 29 ’25, was worth 141,316. In this transaction Chief Medical Officer of this company sold 3,932 shares at a rate of $35.94, taking the stock ownership to the 6,068 shares. Before that another transaction happened on Mar 21 ’25, when Company’s Chief Executive Officer sold 10,031 for $41.23, making the entire transaction worth $413,578. This insider now owns 195,085 shares in total.
CRISPR Therapeutics AG (CRSP) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.33 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -25.38% per share during the next fiscal year.
CRISPR Therapeutics AG (NASDAQ: CRSP) Trading Performance Indicators
Check out the current performance indicators for CRISPR Therapeutics AG (CRSP). In the past quarter, the stock posted a quick ratio of 15.64. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 87.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.52, a number that is poised to hit -1.43 in the next quarter and is forecasted to reach -4.46 in one year’s time.
Technical Analysis of CRISPR Therapeutics AG (CRSP)
Looking closely at CRISPR Therapeutics AG (NASDAQ: CRSP), its last 5-days average volume was 2.13 million, which is a drop from its year-to-date volume of 2.15 million. As of the previous 9 days, the stock’s Stochastic %D was 38.91%. Additionally, its Average True Range was 1.93.
During the past 100 days, CRISPR Therapeutics AG’s (CRSP) raw stochastic average was set at 30.96%, which indicates a significant decrease from 58.70% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 48.08% in the past 14 days, which was lower than the 62.93% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $36.94, while its 200-day Moving Average is $43.50. However, in the short run, CRISPR Therapeutics AG’s stock first resistance to watch stands at $38.77. Second resistance stands at $39.50. The third major resistance level sits at $40.84. If the price goes on to break the first support level at $36.69, it is likely to go to the next support level at $35.35. Now, if the price goes above the second support level, the third support stands at $34.62.
CRISPR Therapeutics AG (NASDAQ: CRSP) Key Stats
There are currently 86,364K shares outstanding in the company with a market cap of 3.29 billion. Presently, the company’s annual sales total 37,310 K according to its annual income of -366,250 K. Last quarter, the company’s sales amounted to 870 K and its income totaled -136,000 K.
